Ondine Biomedical Inc. (OBI.L)

GBp 8.13

(4.84%)

Market Cap (In GBp)

32.82 Million

Revenue (In GBp)

1.2 Million

Net Income (In GBp)

-14.41 Million

Avg. Volume

144.81 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.0-11.4
PE
-
EPS
-
Beta Value
-0.08
ISIN
CA68234M2058
CUSIP
68234M205
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA
Employee Count
-
Website
https://www.ondinebio.com
Ipo Date
2021-12-06
Details
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.